SCHEMBL7978314

SCHEMBL7978314

COC(=O)c1[nH]nc(-c2ccc(C)cc2)c1O

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.53
POLB P06746 2/20 0.51
MAPT P10636 2/20 0.51
RAB9A P51151 2/20 0.51
ALPL P05186 2/20 0.51
MAPK1 P28482 4/20 0.45
ALDH1A1 P00352 5/20 0.43
KMT2A Q03164 3/20 0.43
TDP1 Q9NUW8 1/20 0.43
MAP2K4 P45985 5/20 0.42
MEN1 O00255 2/20 0.41
MAPKAPK3 Q16644 3/20 0.40
MAPK6 Q16659 3/20 0.40
MAPKAPK2 P49137 2/20 0.40
MAPKAPK5 Q8IW41 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10172663 0.85 MAPT (0.51) MAPTRAB9AALPLALDH1A1SMN1; SMN2
SCHEMBL10140869 0.83 MEN1 (0.44) POLBMAPTRAB9AALPLMAPK1
SCHEMBL8179840 0.76 PTGS2 (0.46) POLBMAPTRAB9AALPLALDH1A1
SCHEMBL8166781 0.75 CA12 (0.54)
SCHEMBL11070855 0.75 RAB9A (0.50) KDM4CPOLBMAPTRAB9AALPL
SCHEMBL10172532 0.74 HPGDS (0.60) MAPTRAB9AMAPK1ALDH1A1SMN1; SMN2
SCHEMBL23115860 0.73 KDM4C (0.67) KDM4CPOLBMAPTRAB9AALPL
SCHEMBL16258984 0.73 LMNA (0.43) POLBMAPTRAB9AALPLMAPK1
SCHEMBL7975685 0.73 MAPT (0.41) POLBMAPTRAB9AALPLALDH1A1
SCHEMBL18660404 0.70 KDM4C (1.00) KDM4CPOLBMAPTMAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2805939-B1 Heterocyclic compounds as factor IXA inhibitors. MERCK SHARP & DOHME (US) 2018-06-27 EP disclosed
EP-2805939-A1 Heterocyclic compounds as factor IXA inhibitors. Merck Sharp & Dohme Corp. (US) 2014-11-26 EP disclosed
US-8148363-B2 Heterocyclic compounds as factor IXA inhibitors SCHERING CORPORATION (US) 2012-04-03 US disclosed
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-17 US disclosed
WO-2009143039-A2 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS SCHERING CORPORATION (US) 2009-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS F9, F12, F8 KDM4C 1826/4885POLB 3428/4885MAPT 4510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.